U.S.-listed shares of Novo Nordisk A/S (NYSE:NVO) soared 7.36% during Tuesday’s pre-market session following the approval of its GLP-1 pill by the U.S. Food and Drug Administration (FDA).

Danish Pharma Gains From FDA Approval

The Danish pharmaceutical company’s shares jumped after the FDA gave the green light to its GLP-1 pill, Wegovy on Monday. This marks the first approval of its kind globally.

The company announced that the pill's starting dose of 1.5 milligrams will be available in pharmacies and through select telehealth providers beginning early January, priced at $149 per month.

Patients paying out of pocket can also purchase it at the same rate via President Donald Trump's direct-to-consumer platform, TrumpRx, under an agreement reached with his administration last month.

Novo Nordisk Faces Setbacks, Gains Lead

The approval of the GLP-1 pill comes amidst a challenging ...